Showing results (1-10 of 60) with videos related to
Sort By:
Pageof 6
Current Pharmaceutical Design|July 18, 2013
Molecular hydrogen: new antioxidant and anti-inflammatory therapy for rheumatoid arthritis and related diseasesToru IshibashiCurrent Pharmaceutical Design|May 7, 2019
Therapeutic Efficacy of Molecular Hydrogen: A New Mechanistic InsightToru IshibashiAnticancer Research|May 4, 2005
Determination of optimal dosage for nedaplatin based on pharmacokinetic and toxicodynamic analysisToru Ishibashi, Yoshitaka Yano, Takayoshi OgumaEMBO Reports|April 30, 2003
A novel mechanism for preventing mutations caused by oxidation of guanine nucleotidesToru Ishibashi, Hiroshi Hayakawa, Mutsuo SekiguchiJournal of Pharmaceutical Sciences|April 19, 2019
Population Pharmacokinetics of Baloxavir Marboxil in Japanese Pediatric Influenza PatientsHiroki Koshimichi, Toru Ishibashi, Toshihiro WajimaBritish Journal of Clinical Pharmacology|August 5, 2003
Population pharmacokinetics of platinum after nedaplatin administration and model validation in adult patientsToru Ishibashi, Yoshitaka Yano, Takayoshi OgumaClinical Pharmacokinetics|November 20, 2024
Population Pharmacokinetics of Ensitrelvir in Healthy Participants and Participants with SARS-CoV-2 Infection in the SCORPIO-SR StudyToru Ishibashi, Ryosuke Shimizu, Ryuji KubotaAnticancer Research|May 4, 2005
Optimal sampling and limited sampling strategies for estimation of unbound platinum AUC after nedaplatin infusionToru Ishibashi, Kazuya Fukumura, Yoshitaka Yano, et al.Journal of Pharmaceutical Sciences|December 18, 2018
Population Pharmacokinetic and Exposure-Response Analyses of Baloxavir Marboxil in Adults and Adolescents Including Patients With InfluenzaHiroki Koshimichi, Yoshiyuki Tsuda, Toru Ishibashi, et al.Journal of Pharmaceutical Sciences|March 31, 2015
Prediction of Pharmacokinetics and Pharmacodynamics of Doripenem in Pediatric PatientsYumiko Matsuo, Toru Ishibashi, Kenji Shimamura, et al.Pageof 6